Joel R. Jung joined Renalytix as interim Chief Financial Officer in May 2024. From 2008 – 2020, he also served as CFO for various life sciences, biotech, and diagnostic companies, including Celera Corporation, Agraquest, Inc., BioNano Genomics, and Counsyl, Inc. Most recently, he was Chief Financial Officer at Minerva Surgical, a commercial-stage medical device company. He received his BS in Aeronautical and Astronautical Engineering from Purdue University and his MBA in Finance from the Haas School of Business at the University of California, Berkeley.